The stock of Q32 Bio Inc (QTTB) has seen a -7.10% decrease in the past week, with a -25.00% drop in the past month, and a -3.03% decrease in the past quarter. The volatility ratio for the week is 7.35%, and the volatility levels for the past 30 days are at 7.34% for QTTB. The simple moving average for the last 20 days is -10.68% for QTTB stock, with a simple moving average of -89.70% for the last 200 days.
Is It Worth Investing in Q32 Bio Inc (NASDAQ: QTTB) Right Now?
Moreover, the 36-month beta value for QTTB is -0.03. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy”, 0 as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for QTTB is 4.44M and currently, short sellers hold a 8.67% of that float. On July 04, 2025, QTTB’s average trading volume was 159.96K shares.
QTTB stock’s latest price update
Q32 Bio Inc (NASDAQ: QTTB)’s stock price has decreased by 0.00% compared to its previous closing price of $1.44. However, the company has seen a -7.10% decrease in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-25 that — Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience — WALTHAM, Mass., June 25, 2025 /PRNewswire/ — Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the appointment of Adrien Sipos, M.D.
Analysts’ Opinion of QTTB
Many brokerage firms have already submitted their reports for QTTB stocks, with Piper Sandler repeating the rating for QTTB by listing it as a “Neutral”. The predicted price for QTTB in the upcoming period, according to Piper Sandler is $4 based on the research report published on February 11, 2025 of the current year 2025.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see QTTB reach a price target of $3, previously predicting the price at $22. The rating they have provided for QTTB stocks is “Market Perform” according to the report published on February 11th, 2025.
Raymond James gave a rating of “Outperform” to QTTB, setting the target price at $22 in the report published on December 11th of the previous year.
QTTB Trading at -13.75% from the 50-Day Moving Average
After a stumble in the market that brought QTTB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.32% of loss for the given period.
Volatility was left at 7.34%, however, over the last 30 days, the volatility rate increased by 7.35%, as shares sank -25.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.61% lower at present.
During the last 5 trading sessions, QTTB fell by -7.10%, which changed the moving average for the period of 200-days by -96.88% in comparison to the 20-day moving average, which settled at $1.6122. In addition, Q32 Bio Inc saw -92.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Q32 Bio Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for QTTB
The total capital return value is set at -0.87%. Equity return is now at value -267.20%, with -51.68% for asset returns.
Based on Q32 Bio Inc (QTTB), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at -3.58. The debt to equity ratio resting at 3.33. The interest coverage ratio of the stock is -38.88.
Currently, EBITDA for the company is -45.3 million with net debt to EBITDA at 1.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.71.
Conclusion
To wrap up, the performance of Q32 Bio Inc (QTTB) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
